Celltrion to Begin Remsima (infliximab) Clinical Trials in China

Biosimilar News

Sources are reporting that Celltrion has received clearance from the China Food and Drug Administration (CFDA) to conduct clinical trials of Remsima (infliximab), a biosimilar of Janssen’s Remicade.  This is the first time a non-Chinese company will begin clinical trials of a biosimilar mAb in China.

Remsima is approved in the U.S. and the E.U.

Download PDF

Comments are closed.